From proteomics to prescriptionthe search for COPD biomarkers

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 6, Issue 4, 2009, Pages 298-303

  Nicholas, Benjamin L ^a   O'Connor, C David ^b   Djukanovic, Ratko ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Biomarkers; Bodily secretions; Chronic obstructive pulmonary disease; Diagnosis; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN A; CALGRANULIN B; CLARA CELL SECRETORY PROTEIN 10; COLLAGEN; FIBRINOGEN; FIBRONECTIN; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; SECRETORY PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CHEMICAL LABELING; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LUNG LAVAGE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPUTUM ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TWO DIMENSIONAL GEL ELECTROPHORESIS; DIAGNOSTIC IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOMICS; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PATHOLOGY; REVIEW;

BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOMICS; HUMANS; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 70350457544     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550903049140     Document Type: Conference Paper

References (77)

1. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, la Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006; 19:189-199.
2. Hurst JR, Perera WR,Wilkinson TM, Donaldson GC,Wedzicha JA. Exacerbation of chronic obstructive pulmonary disease: Panairway and systemic inflammatory indices. Proc Amer Thorac Soc 2006; 3:481-482.
3. Wielders PL, Dekhuijzen PN. Disease monitoring in chronic obstructive pulmonary disease: Is there a role for biomarkers? Eur Respir J 1997; 10:2443-2445.
4. Aldonyte R, Eriksson S, Piitulainen E, Wallmark A, Janciauskiene S. Analysis of systemic biomarkers in COPD patients. COPD 2004; 1:155-164.
5. Casado B, Iadarola P, Luisetti M, Kussmann M. Proteomicsbased diagnosis of chronic obstructive pulmonary disease: The hunt for new markers. Expert Rev Proteom 2008; 5:693-704.
6. Barnes PJ, Stockley RA. COPD: Current therapeutic interventions and future approaches. Eur Respir J 2005; 25:1084-1106.
7. Pinto-Plata V, Toso J, Lee K, Bilello J, Mullerova H, De SM, Vessey R, Celli B. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: Correlation with clinical parameters. Proc Amer Thorac Soc 2006; 3: 465-466.
8. Merkel D, Rist W, Seither P, Weith A, Lenter MC. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surfaceenhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005; 5:2972-2980.
9. Tzortzaki EG, Lambiri I, Vlachaki E, Siafakas NM. Biomarkers in COPD. Curr Med Chem 2007; 14:1037-1048.
10. Bowler RP, Ellison MC, Reisdorph N. Proteomics in pulmonary medicine. Chest 2006; 130:567-574.
11. Ashitani J, Mukae H, Arimura Y, Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002; 41:181-185.
12. Sunderland T, Gur RE, Arnold SE. The use of biomarkers in the elderly: Current and future challenges. Biol Psych 2005; 58:272-276.
13. Lakhan SE. Schizophrenia proteomics: Biomarkers on the path to laboratory medicine? Diagn Pathol 2006; 1:11.
14. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
15. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY. Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genom 2008; 9:246.
16. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: A state-of-the-art review. Clin Microbiol Rev 2001; 14:336-363.
17. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434-1440.
18. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
19. Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers 2002; 7:1-32.
20. Jeffery PK, Laitinen A, Venge P. Biopsymarkers of airway inflammation and remodelling. Respir Med 2000; 94 Suppl F:S9-15.
21. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:822-832.
22. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008; 31:416-469.
23. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61:17-22.
24. Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR, et al. Circulating fibronectin to C-reactive protein ratio and mortality: A biomarker in COPD? Eur Respir J 2008; 32:1451-1457.
25. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: A prospective study. Thorax 2007; 62:515-520.
26. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128:1995-2004.
27. Roth M. Pathogenesis of COPD. Part III. Inflammation in COPD. Int J Tuberc Lung Dis 2008; 12:375-380.
28. Kranenburg AR, Willems-Widyastuti A, Moori WJ, Sterk PJ, Alagappan VK, de Boer WI, Sharma HS. Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol 2006; 126:725-735.
29. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645-2653.
30. Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T, Sato H, Masuda M, Itoh H. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005; 25:885-890.
31. Szoltysik E, Kucharz EJ. Serum markers of collagen metabolism in patients with diseases of the respiratory system. Rom J Intern Med 1993; 31:119-122.
32. Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, Demeo DL, Reilly JJ, Kwiatkowski DJ, Chapman HA, Laird N, et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004; 13:1649-1656.
33. Ito M, Hanaoka M, Droma Y, Hatayama O, Sato E, Katsuyama Y, Fujimoto K, Ota M. The association of transforming growth factor beta 1 gene polymorphisms with the emphysema phenotype of COPD in Japanese. Intern Med 2008; 47:1387-1394.
34. Sin DD, Man SF. Biomarkers in COPD: Are we there yet? Chest 2008; 133:1296-1298.
35. Erin EM, Jenkins GR, Kon OM, Zacharasiewicz AS, Nicholson GC, Neighbour H, Tennant RC, Tan AJ, Leaker BR, Bush A, et al. Optimized dialysis and protease inhibition of sputum dithiothreitol supernatants. Am J Respir Crit Care Med 2008; 177:132-141.
36. Noel-Georis I, Bernard A, Falmagne P, Wattiez R. Database of bronchoalveolar lavage fluid proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 771:221-236.
37. Plymoth A, Yang Z, Lofdahl CG, Ekberg-Jansson A, Dahlback M, Fehniger TE, Marko-Varga G, Hancock WS. Rapid proteome analysis of bronchoalveolar lavage samples of lifelong smokers and never-smokers by micro-scale liquid chromatography and mass spectrometry. Clin Chem 2006; 52:671-679.
38. Nicholas B, Skipp P, Mould R, Rennard S, Davies DE, O'Connor CD, Djukanovic R. Shotgun proteomic analysis of human-induced sputum. Proteomics 2006; 6:4390-4401.
39. Millea KM, Krull IS, Chakraborty AB, Gebler JC, Berger SJ. Comparative profiling of human saliva by intact protein LC/ESITOF mass spectrometry. Biochim Biophys Acta 2007; 1774:897-906.
40. Hu S, Xie Y, Ramachandran P, Ogorzalek Loo RR, Li Y, Loo JA, Wong DT. Large-scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and twodimensional gel electrophoresis-mass spectrometry. Proteomics 2005; 5:1714-1728.
41. Hu S, Yu T, Xie Y, Yang Y, Li Y, Zhou X, Tsung S, Loo RR, Loo JR, Wong DT. Discovery of oral fluid biomarkers for human oral cancer by mass spectrometry. Cancer Genomics Proteomics 2007; 4:55-64.
42. Hardt M, Thomas LR, Dixon SE, Newport G, Agabian N, Prakobphol A, Hall SC, Witkowska HE, Fisher SJ. Toward defining the human parotid gland salivary proteome and peptidome: Identification and characterization using 2D SDS-PAGE, ultrafiltration, HPLC, and mass spectrometry. Biochemistry 2005; 44:2885-2899.
43. Huang CM. Comparative proteomic analysis of human whole saliva. Arch Oral Biol 2004; 49:951-962.
44. Xie H, Rhodus NL, Griffin RJ, Carlis JV, Griffin TJ. A catalogue of human saliva proteins identified by free flow electrophoresisbased peptide separation and tandem mass spectrometry. Mol Cell Proteomics 2005; 4:1826-1830.
45. Amado FM, Vitorino RM, Domingues PM, Lobo MJ, Duarte JA. Analysis of the human saliva proteome. Expert Rev Proteomics 2005; 2:521-539.
46. Kipnis E, Hansen K, Sawa T, Moriyama K, Zurawel A, Ishizaka A, Wiener-Kronish J. Proteomic analysis of undiluted lung epithelial lining fluid. Chest 2008; 134:338-345.
47. Debat H, Eloit C, Blon F, Sarazin B, Henry C, Huet JC, Trotier D, Pernollet JC. Identification of human olfactory cleft mucus proteins using proteomic analysis. J Proteome Res 2007; 6:1985-1996.
48. Ghafouri B, Irander K, Lindbom J, Tagesson C, Lindahl M. Comparative proteomics of nasal fluid in seasonal allergic rhinitis. J Proteome Res 2006; 5:330-338.
49. Casado B, Pannell LK, Viglio S, Iadarola P, Baraniuk JN. Analysis of the sinusitis nasal lavage fluid proteome using capillary liquid chromatography interfaced to electrospray ionization-quadrupole time of flight-tandem mass spectrometry. Electrophoresis 2004; 25:1386-1393.
50. Casado B, Pannell LK, Iadarola P, Baraniuk JN. Identification of human nasal mucous proteins using proteomics. Proteomics 2005; 5:2949-2959.
51. Bryborn M, Adner M, Cardell LO. Psoriasin, one of several new proteins identified in nasal lavage fluid from allergic and nonallergic individuals using 2-dimensional gel electrophoresis and mass spectrometry. Respir Res 2005; 6:118.
52. Malmstrom J, Larsen K, Malmstrom L, Tufvesson E, Parker K, Marchese J, Williamson B, Patterson D, Martin S, Juhasz P, et al. Nanocapillary liquid chromatography interfaced to tandem matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry: mapping the nuclear proteome of human fibroblasts. Electrophoresis 2003; 24:3806-3814.
53. Malmstrom J, Larsen K, Malmstrom L, Tufvesson E, Parker K, Marchese J, Williamson B, Hattan S, Patterson D, Martin S, et al. Proteome annotations and identifications of the human pulmonary fibroblast. J Proteome Res 2004; 3:525-537.
54. Bogatkevich GS, Ludwicka-Bradley A, Singleton CB, Bethard JR, Silver RM. Proteomic analysis of CTGF-activated lung fibroblasts: Identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol 2008; 295:L603-L611.
55. Kelsen SG, Duan X, Ji R, Perez O, Liu C, Merali S. Cigarette smoke induces an unfolded protein response in the human lung: A proteomic approach. Am J Respir Cell Mol Biol 2008; 38:541-550.
56. Li C, Zhan X, Li M, Wu X, Li F, Li J, Xiao Z, Chen Z, Feng X, Chen P, et al. Proteomic comparison of two-dimensional gel electrophoresis profiles from human lung squamous carcinoma and normal bronchial epithelial tissues. Genomics Proteomics Bioinformatics 2003; 1:58-67.
57. Zhao H, Adler KB, Bai C, Tang F, Wang X. Epithelial proteomics in multiple organs and tissues: Similarities and variations between cells, organs, and diseases. J Proteome Res 2006; 5:743-755.
58. Jin M, Opalek JM, Marsh CB, Wu HM. Proteome comparison of alveolar macrophages with monocytes reveals distinct protein characteristics. Am J Respir Cell Mol Biol 2004; 31:322-329.
59. Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, Karlsson AS, Silvestrini R, Smallwood D, Vlahos R, et al. Serum amyloid a is a biomarker of acute exacerbations exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:269-278.
60. Bai Y, Galetskiy D, Damoc E, Paschen C, Liu Z, Griese M, Liu S, Przybylski M. High resolution mass spectrometric alveolar proteomics: Identification of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 2004; 4:2300-2309.
61. Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, Myllarniemi M, Kinnula VL. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J Proteome Res 2008; 7:5125-5132.
62. Casado B, Iadarola P, Pannell LK, Luisetti M, Corsico A, Ansaldo E, Ferrarotti I, Boschetto P, Baraniuk JN. Protein expression in sputum of smokers and chronic obstructive pulmonary disease patients: A pilot study by CapLC-ESI-Q-TOF. J Proteome Res 2007; 6:4615-4623.
63. Reynolds SD, Reynolds PR, Pryhuber GS, Finder JD, Stripp BR. Secretoglobins SCGB3A1 and SCGB3A2 define secretory cell subsets in mouse and human airways. Am J Respir Crit Care Med 2002; 166:1498-1509.
64. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008; 178:444-452.
65. Ekblad L, Baldetorp B, Ferno M, Olsson H, Bratt C. In-source decay causes artifacts in SELDI-TOF MS spectra. J Proteome Res 2007; 6:1609-1614.
66. SemmesOJ, Feng Z, Adam BL, Banez LL, BigbeeWL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005; 51:102-112.
67. Lorenz E, Muhlebach MS, Tessier PA, Alexis NE, Duncan HR, Seeds MC, Peden DB, Meredith W. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008; 102:567-573.
68. Uhlen M. Affinity as a tool in life science. Biotechniques 2008; 44:649-654.
69. Hober S, Uhlen M. Human protein atlas and the use of microarray technologies. Curr Opin Biotechnol 2008; 19:30-35.
70. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serumof patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13Clabeled peptide standards. Proteomics 2004; 4:1175-1186.
71. Anderson L, Hunter CL. Quantitativemass spectrometricmultiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006; 5:573-588.
72. McDonnell LA, Heeren RM. Imaging mass spectrometry. Mass Spectrom Rev 2007; 26:606-643.
73. Khatib-Shahidi S, Andersson M, Herman JL, Gillespie TA, Caprioli RM. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Anal Chem 2006; 78:6448-6456.
74. Andersson M, Groseclose MR, Deutch AY, Caprioli RM. Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction. Nat Meth 2008; 5:101-108.
75. Sinha TK, Khatib-Shahidi S, Yankeelov TE, Mapara K, Ehtesham M, Cornett DS, Dawant BM, Caprioli RM, Gore JC. Integrating spatially resolved three-dimensional MALDI IMS with in vivo magnetic resonance imaging. Nat Meth 2008; 5: 57-59.
76. Bachi A, Bonaldi T. Quantitative proteomics as a new piece of the systems biology puzzle. J Proteomics 2008;71:357-367.
77. Preisinger C, von KA, Matallanas D, Kolch W. Proteomics and phosphoproteomics for themapping of cellular signalling networks. Proteomics 2008;8:4402-4415.